A comparative efficacy trial between cefuroxime and cloxacillin as intramammary treatments for clinical mastitis in lactating cows on commercial dairy farms.

AIMS: To assess the efficacy of a commercial intramammary preparation containing cefuroxime as a treatment for clinical mastitis in lactating dairy cows.

METHODS: Clinical mastitis cases (n=440) were identified during early to mid lactation on 36 seasonally-calving commercial dairy herds in south-western Victoria, Australia, that ranged in size from 140 to 550 cows. A milk sample for bacterial culture was collected from each affected quarter prior to treatment. Cases were treated using a commercial intramammary antibiotic product containing either 250 mg cefuroxime or 200 mg cloxacillin, according to the manufacturer's recommendations, and the recommended milk with-holding period was observed. The assessment of clinical cure of each case was made by the farm owner/manager at the end of the milk with-holding period. Post-treatment milk samples were taken from clinically cured quarters at each of three consecutive milkings, commencing 7 days after the end of the milk with-holding period and submitted for bacterial culture.

RESULTS: Pathogenic bacteria were isolated from 252/416 (60.6%) pre-treatment milk samples submitted from eligible cases. Streptococcus uberis was the most frequent isolate, being cultured from 31.7% of cases. Staphylococcus aureus was isolated from 18.3% of pre-treatment samples, and Esherichia coli from 7.0%. The clinical cure rate for all eligible cases was 81.7%. There was no significant difference in clinical cure rates between cases treated with cefuroxime (186/225=82.7%) and cases treated with cloxacillin (154/191=80.6%). The trial had 80% power to detect a significant difference if the actual cure rates differed by at least 12.6%. There was a superior clinical response rate (p=0.04) for mastitis cases from which E. coli was isolated that were treated with cefuroxime (18/19=95%) compared with cloxacillin 6/10=60%), but case numbers were low (n=29). The overall bacteriological cure rate for the trial was 70% (69/98 cases assessed). There was no significant difference (p=0.27) in bacteriological cure rate between cases treated with cefuroxime (42/56=75%) and cases treated with cloxacillin (27/42=64%).

CONCLUSIONS: This trial demonstrated that cefuroxime was an effective intramammary treatment for clinical mastitis and had similar clinical and bacteriological cure rates to cloxacillin, an accepted industry-standard product. Activity against Gram-negative and Gram-positive bacteria was demonstrated for cefuroxime which, along with the economic benefits of less discarded milk compared with other antibiotic preparations, indicated that cefuroxime is likely to be an appropriate intramammary antibiotic for the treatment of clinical mastitis in commercial dairy herds during early to mid lactation in Victoria, Australia.